Narirutin downregulates lipoxygenase-5 expression and induces G0/G1 arrest in triple-negative breast carcinoma cells

• Published in: Biochimica et biophysica acta. General subjects Vol. 1867; no. 6; p. 130340
• Main Authors: Singh, Shilpi, Maurya, Akhilesh Kumar, Meena, Abha, Mishra, Nidhi, Luqman, Suaib
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2023
• Subjects: Cancer chemoprevention; Cyclooxygenase 2; Flavanones - pharmacology; Humans; Lipoxygenase - therapeutic use; Lipoxygenase-5, Cyclooxygenase-2; MDAMB-231; Molecular Docking Simulation; Narirutin; Ornithine Decarboxylase; Triple Negative Breast Neoplasms - metabolism; Triple-negative breast cancer; Cancer chemoprevention; Lipoxygenase-5, Cyclooxygenase-2; SRB; BBB; SPARC; DMSO; NaOH; FACS; MTT; Triple-negative breast cancer; PDB; MTX; NRU; DMEM; MDAMB-231; FBS; IC50; Ab/Am; GSH; PBS; PGE2; PEP-A; SOD; Narirutin; TCA; HEPES; PI; DFMO; GAPDH; PCR

Triple-negative breast cancer (TNBC) accounts for 20% of breast cancer that does not express HER2, progesterone and estrogen receptors. It is associated with a high mortality rate, morbidity, metastasis, recurrence, poor prognosis and resistance to chemotherapy. Lipoxygenase-5 (LOX-5), cyclooxygenas...